-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevasemten in Becker Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevasemten in Becker Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevasemten in Becker Muscular Dystrophy Drug Details: Sevasemten (EDG-5506) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vamorolone in Becker Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vamorolone in Becker Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vamorolone in Becker Muscular Dystrophy Drug Details: Vamorolone (Agamree) acts...
-
Product Insights
Becker Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Becker Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Becker Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewHistone Deacetylase 1 – Drugs In Development, 2024
The Histone Deacetylase 1 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Hematological Disorders, and Genetic Disorders which include indications of Breast Cancer, Non-Small Cell Lung Cancer, Alzheimer's Disease, Multiple Sclerosis, Sickle Cell Disease, Hemoglobinopathies, Duchenne Muscular Dystrophy, and Becker...
-
Product Insights
NewHistone Deacetylase 2 – Drugs In Development, 2024
The Histone Deacetylase 2 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Hematological Disorders, and Genetic Disorders which include indications of Diffuse Large B-Cell Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alzheimer's Disease, Huntington Disease, Sickle Cell Disease, Hemoglobinopathies,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevasemten in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevasemten in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevasemten in Duchenne Muscular Dystrophy Drug Details: Sevasemten (EDG-5506) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Polymyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Polymyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Polymyositis Drug Details: Froniglutide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Dermatomyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Dermatomyositis Drug Details: Froniglutide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARM-210 in Ventricular Tachycardia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARM-210 in Ventricular Tachycardia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARM-210 in Ventricular Tachycardia Drug Details: ARM-210 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Inclusion Body Myositis (IBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide...